The Precision Medicine Company
Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies
AlphaBiomics’ CEO Anthony Williamson invited to speak at workshop on how the microbiome influences the therapeutic effectiveness of drugs.
Read more here.
The Precision Medicine Company
Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies
Winner of the 2018 European Innovation Quickfire Challenge (read more)